New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
13:59 EDTDRTXDurata Therapeutics CEO buys 3,000 shares
Durata Therapeutics CEO Paul Edick purchased 3,000 shares of the company's stock at a price of $15.23 each on June 12, according to a regulatory filing.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use